drugset

drugset / Trial / NCT00557661

Safety Study of CD-NP in Heart Failure

NCT00557661 ↗

Phase 1 Completed 20 enrolled Nile Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label study designed to determine the safety, tolerability and pharmacodynamics of CD-NP infusions in heart failure patients.

Timeline

Start: 2007-11
Primary completion: —
Completion: 2008-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cenderitide	Peptide	—	Intravenous

Indications